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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S252Figure 1. Presentation of the mean values of the KOOS subscales for different grades of
radiographic changes in the right knee joint (n¼302). Normative values are age
matched values from Paradowski et al. 2006.
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IMPACT OF PREDICTABLE VERSUS UNPREDICTABLE INTERMITTENT
PAIN ON SOCIAL ROLE PARTICIPATION IN SUBJECTS WITH KNEE
OSTEOARTHRITIS
T. Kendzerska y,z, M. Gignac y,x, I. Stanaitis z, G. Hawker y,z. yUniv. of
Toronto, Toronto, ON, Canada; zWomen's Coll. Hosp., Toronto, ON,
Canada; x Toronto Western Res. Inst., Toronto, ON, Canada
Purpose: Focus group discussions in individuals with hip/knee osteo-
arthritis (OA) identiﬁed two types of OA pain - a constant background
pain and a less frequent, but more intense and often unpredictable,
intermittent pain - with the latter having the greatest impact on social
role participation. These ﬁndings led to the creation of the OARSI-
OMERACT measure of Intermittent and Constant OA Pain (ICOAP). The
current study sought to validate focus group ﬁndings with respect to the
inﬂuence of OA pain predictability on participation restrictions.
Methods: In an established community cohort aged 50+ years with hip/
knee OA, we assessed demographic characteristics, OA pain (ICOAP
Knee) and disability (KOOS-PS), and participation restrictions. ICOAP is
comprised of two subscales: a 5-item scale assesses constant pain and
a 6-item scale assesses intermittent pain, or ‘pain that comes and goes’.
Subscale scores are created by summing item scores and transforming
to 0-100; higher scores indicate greater pain. Those with intermittent
pain were asked to report the frequency with which the pain occurs
‘without warning’ (i.e., unpredictably) and ‘after a trigger’ (i.e.,
predictably), from 0 (never) to 4 (very often). To assess social role
participation, participants were asked the degree to which they had
given up or limited time spent in important roles due to their hip/knee
arthritis, from 1, not at all, to 5, a great deal. Logistic regressionwas used
to examine the effect of the frequent unpredictable and frequent
predictable intermittent knee pain (often/very often - yes/no) on
participation restrictions (roles restricted quite a bit/a great deal - yes/
no), controlling for age, gender, and OA severity (ICOAP subscale scores;
KOOS-PS score). Speciﬁcally, we assessed for interactions between
ICOAP intermittent scores and each of frequent unpredictable and
predictable knee pain on social role restrictions.
Results: 265 cohort participants with complete datawere included in our
analyses. Theirmean agewas 65 years (SD 10) and 75%were female. 69.6%
reported intermittent knee pain only, 22.5% constant knee pain only, and
7.9%bothpain types.Median (IQR) ICOAP intermittent and constant scores
were 37.5 (20.8-45.8) and 0 (0), respectively. Of the 186 subjects who re-
ported intermittent pain, 14.6% reported frequent unpredictable pain and
10.9% reported frequent predictable pain. 40% and 36.6% had limited time
spent in ‘important roles’ ‘somewhat’ or ‘quite a bit’. Controlling for age,
sex, ICOAPsubscale andKOOS-PS scores,we found a signiﬁcant interaction
between ICOAP intermittent pain severity and frequency of unpredictable
pain on participation restrictions (p¼0.03), such that for individuals with
similar levels of intermittent pain severity, the impact on social role
participationwasgreater for thosewithmore frequent versus less frequent
unpredictable intermittent pain. No interaction was found between
intermittent pain severity and frequent predictable pain.
Conclusion: Our results conﬁrm ﬁndings from qualitative research that,
controlling for other factors, social role restrictions are greatest among
those with intermittent knee pain that frequently occurs warning
inﬂuences. Further studies in larger cohorts, and with greater variability
in pain types, is warranted to conﬁrm our ﬁndings and, if conﬁrmed, to
elucidate potential explanations.481
EFFICACY AND TOLERABILITY OF CELECOXIB AND NAPROXEN VS
PLACEBO IN HISPANIC PATIENTS WITH KNEE OSTEOARTHRITIS
M.N. Essex, R. Behar, M.A. O'Connell, P. Bhadra Brown. Pﬁzer Inc., New
York, NY, USA
Purpose: The primary objective of this study was to determine if cel-
ecoxib 200 mg once daily (qd) was as effective as naproxen 500 mg
twice daily (bid) in the treatment of osteoarthritis (OA) of the knee in
Hispanic patients.
Methods: Hispanic patients aged 45 years with diagnosed knee OA in
a ﬂare state and with a functional capacity classiﬁcation of I to III were
randomized in a 2:2:1 manner to receive celecoxib 200 mg qd, nap-
roxen 500 mg bid, or placebo for 6 weeks. The primary efﬁcacy variable
was the change in the Patient's Assessment of Arthritis Pain at 6 weeks
compared with baseline. Secondary efﬁcacy variables were change in
Patient's and Physician's Global Assessments of Arthritis from baseline
to Week 6/early termination, change in Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) scores from baseline to
Week 6/early termination, change in American Pain Society pain scores,
score on Pain Satisfaction Scale, Patient Health Questionnaire (PHQ-9)
responses, and measurement of upper GI (UGI) tolerability.
Results: 318 subjects were randomized; 239 completed the trial (96
celecoxib, 96 naproxen, 47 placebo) and formed the primary analysis
population. Celecoxib was observed to be as effective as naproxen in
reducing OA pain (least squares mean change from baseline -39.7,
standard error [SE] 2.7 for celecoxib, -36.9, SE 2.6 for naproxen; the
lower bound of the 2-sided 95% conﬁdence interval for the treatment
difference [naproxen-celecoxib] was above -10 mm). Similar efﬁcacy
was seen for celecoxib and naproxen in secondary outcomes. No
statistically signiﬁcant differences between celecoxib and naproxen
groups were seen on the Patient's or Physician's Global Assessments of
Arthritis, WOMAC Index scores, UGI, Pain Satisfaction Scale score, and
PHQ-9. The incidence of adverse events (AE) and treatment-related AEs
was similar among treatment groups. 13 subjects withdrew from the
study due to AEs (3 celecoxib, 9 naproxen, 1 placebo); 10 discontinued
due to treatment-related AEs (2 celecoxib, 7 naproxen, 1 placebo). UGI
events (moderate or severe nausea, abdominal pain, and/or dyspepsia)
were reported by 3 celecoxib, 4 naproxen, and 1 placebo subject. One
subject in the naproxen group had a GI hemorrhage; this was consid-
ered a treatment-related AE and resulted in withdrawal from the study.
Conclusions: Celecoxib 200 mg qdwas as effective as naproxen 500mg
bid in the treatment of signs and symptoms of knee OA in Hispanic
subjects. Celecoxibwas shown to be safe andwell tolerated in this study
population. This information may be of use to physicians treating
Hispanic patients with OA.482
RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN
ASIAN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
M.N. Essex, M.A. O'Connell, R. Behar, P. Bhadra Brown. Pﬁzer Inc, New
York, NY, USA
Purpose: Celecoxib is an effective treatment for osteoarthritis (OA);
however, its efﬁcacy and safety proﬁle has not been extensively studied
in different ethnic populations. Differences in therapeutic response to
pharmacologic agents have been found in the Asian population, but
there are limited data for OA treatments. This study was designed to
compare analgesic efﬁcacy, tolerability, and safety of celecoxib, nap-
roxen, and placebo in an Asian American population with OA of the
knee.
Methods: Eligible patients in this 6-week, multicenter, randomized,
double-blind, placebo-controlled, parallel-group study were aged  45
years, of self-reported Asian descent, and with OA of the knee in a ﬂare
state and a functional capacity classiﬁcation of I to III. Patients were
randomized to 1 of 3 regimens: celecoxib 200 mg once daily (qd),
naproxen 500 mg twice daily (bid), or placebo, in a 2:2:1 ratio. The
primary efﬁcacy variable was the change in the Patient's Assessment of
Arthritis Pain at Week 6 compared with baseline using a 100 mm visual
analog scale (VAS). Secondary efﬁcacy variables included Patient's and
Physician's Global Assessment of Arthritis, Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC), Pain Satisfaction
Scale, Patient Health Questionnaire (PHQ-9), and American Pain Society
(APS) pain scores. Other secondary variables included evaluations of
